Neuroplasticity, the brain’s capacity to reorganise its structure and function, is a transdiagnostic feature across psychiatric and neurodegenerative diseases and a putative mechanism of action for pharmacological interventions. [¹¹C]-UCBJ positron emission tomography (PET), which quantifies synaptic vesicle glycoprote...
C. Agnorelli, J. Peill, D. Kurtin et al.· bioRxiv· 0 citations
Findings support a mechanism by which elevated dopamine may impair motivational coding by reducing amplification of goal-relevant information, with potential relevance to negative symptoms such as apathy and anhedonia.
C. Zauchenberger, L. Vano, M. Veronese et al.· Biological Psychiatry· 0 citations
Novel antipsychotics-particularly muscarinic agonists-may expand options for patients who cannot tolerate or do not respond adequately to D2 antagonists, and their ultimate clinical utility will be determined by comparative effectiveness and tolerability versus established SGAs, impact on functioning, and clear pathway...
S. Jauhar· International Journal of Neu...· 0 citations
It is found that rapid relapse was not over-represented among those who discontinued treatment, which is not the pattern expected if rapid relapse following paliperidone discontinuation were commonly a pharmacological discontinuation effect.
Krisya Louie, S. Jauhar, J. Rubio et al.· Lancet psychiatry· 1 citation
These findings bridge genetic risk at the 22q11.2 locus with dopamine dysfunction and large-scale networks, offering novel insights into the neurobiology of 22q11DS and related neuropsychiatric risk.
V. Mancini, M. Rogdaki, S. Jauhar et al.· Molecular Psychiatry· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
